Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$5.43 -2.9%	$5.23	$3.30 ▼ $13.09	$660.02M	0.83	673,511 shs	563,289 shs
KOD Kodiak Sciences	$3.70 -2.1%	$3.85	$1.92 ▼ $11.60	$195.21M	2.27	343,470 shs	275,486 shs
MGTX MeiraGTx	$6.61 -0.9%	$5.97	$3.85 ▼ $8.88	$531.18M	1.17	383,265 shs	928,477 shs
URGN Urogen Pharma	$13.49 +2.9%	$9.34	$3.42 ▼ $18.15	$622.02M	0.4	1.06 million shs	2.27 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	0.00%	-3.21%	-2.51%	+20.40%	-53.27%
KOD Kodiak Sciences	0.00%	+2.21%	+7.25%	+31.67%	+57.45%
MGTX MeiraGTx	0.00%	+4.26%	+27.61%	-2.51%	+57.01%
URGN Urogen Pharma	0.00%	-7.92%	+233.91%	+21.97%	-19.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMTX Immatics	2.8583 of 5 stars	3.6	4.0	0.0	2.8	1.7	0.0
KOD Kodiak Sciences	4.3863 of 5 stars	3.0	4.0	4.6	3.0	3.3	0.0
MGTX MeiraGTx	4.4066 of 5 stars	3.5	2.0	4.8	3.0	2.5	0.6
URGN Urogen Pharma	4.5915 of 5 stars	4.5	2.0	4.5	3.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMTX Immatics	3.20	Buy	$14.67	170.10% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	143.24% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	263.09% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	143.57% Upside

Current Analyst Ratings Breakdown

Latest KOD, URGN, MGTX, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/3/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/23/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $15.00
5/22/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $3.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMTX Immatics	$168.65M	3.91	$0.24 per share	22.22	$5.12 per share	1.06
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
MGTX MeiraGTx	$33.28M	15.96	N/A	N/A	$0.87 per share	7.60
URGN Urogen Pharma	$90.40M	6.88	N/A	N/A	($0.21) per share	-64.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMTX Immatics	$16.47M	-$0.17	N/A	N/A	N/A	-14.73%	-4.52%	-3.34%	8/12/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	17.39	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)

Latest KOD, URGN, MGTX, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMTX Immatics	N/A	10.28	10.28
KOD Kodiak Sciences	N/A	4.62	4.62
MGTX MeiraGTx	2.34	1.53	1.51
URGN Urogen Pharma	4.77	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMTX Immatics	64.41%
KOD Kodiak Sciences	89.06%
MGTX MeiraGTx	67.48%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
IMTX Immatics	N/A
KOD Kodiak Sciences	45.90%
MGTX MeiraGTx	7.50%
URGN Urogen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMTX Immatics	260	121.55 million	N/A	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable

KOD, URGN, MGTX, and IMTX Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 27 at 10:00 AM | prnewswire.com

Urogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?

June 24, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts

June 24, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by Brokerages

June 24, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 23, 2025 | globenewswire.com

Lowey Dannenberg Notifies UroGen Pharma Ltd. (â€œUroGenâ€ or the â€œCompanyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

June 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 22, 2025 | prnewswire.com

Stocks With Rising Relative Price Strength: UroGen Pharma

June 20, 2025 | msn.com

HC Wainwright Has Negative View of Urogen Pharma Q2 Earnings

June 20, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What Happened

June 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 18, 2025 | globenewswire.com

HC Wainwright Decreases Earnings Estimates for Urogen Pharma

June 18, 2025 | marketbeat.com

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy

June 17, 2025 | msn.com

UroGen Pharma (NASDAQ:URGN) Trading Down 7.7% - Time to Sell?

June 17, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 17, 2025 | prnewswire.com

UroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in May

June 17, 2025 | marketbeat.com

URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses

June 16, 2025 | accessnewswire.comA

Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN

June 16, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGN

June 16, 2025 | accessnewswire.comA

UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade

June 16, 2025 | marketbeat.com

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action

June 16, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, URGN, MGTX, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

$5.43 -0.16 (-2.86%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.65 +0.22 (+4.05%)

As of 04:05 AM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Kodiak Sciences NASDAQ:KOD

$3.70 -0.08 (-2.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.18 +0.48 (+12.97%)

As of 04:00 AM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

MeiraGTx NASDAQ:MGTX

$6.61 -0.06 (-0.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.88 +2.27 (+34.34%)

As of 04:00 AM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Urogen Pharma NASDAQ:URGN

$13.49 +0.38 (+2.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.56 +0.07 (+0.49%)

As of 05:22 AM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time